Vitamin D receptor activator-associated calcium-alkali syndrome-like phenotype without calcium supplementation: a case series of seven patients.

IF 1 Q4 UROLOGY & NEPHROLOGY
Takuya Kumagai, Tsuyoshi Ono
{"title":"Vitamin D receptor activator-associated calcium-alkali syndrome-like phenotype without calcium supplementation: a case series of seven patients.","authors":"Takuya Kumagai, Tsuyoshi Ono","doi":"10.1007/s13730-026-01207-1","DOIUrl":null,"url":null,"abstract":"<p><p>Vitamin D receptor activators (VDRAs) are widely prescribed for osteoporosis and CKD-mineral and bone disorder in Japan. Although hypercalcemia and acute kidney injury (AKI) are recognized adverse effects, metabolic alkalosis in these patients has received limited attention as a feature of calcium-alkali syndrome (CAS).We retrospectively reviewed patients with VDRA-associated hypercalcemia at our institution between April 2016 and June 2026, applying study-defined operational criteria for a CAS-like phenotype: hypercalcemia, elevated bicarbonate compatible with a metabolic alkalosis component (HCO₃⁻ ≥ 26 mmol/L), and AKI (KDIGO criteria). Seven elderly women fulfilled all criteria. Six received eldecalcitol (0.75 μg/day) and one received alfacalcidol (1.0 μg/day). Underlying CKD was present in six patients.Time from initiation to onset ranged from 1 to 120 months (median 18 months). Three cases had no identified exogenous alkali source. The serum Na-Cl difference was elevated in all patients (range 36-53 mEq/L). Renal outcomes were complete recovery in three patients, partial recovery in two, and non-recovery in one; one patient died of worsening heart failure.VDRA-associated hypercalcemia can present as a CAS-like phenotype even without calcium supplementation, and renal outcomes may be irreversible. Because the temporal relationship between hypercalcemia and metabolic alkalosis cannot be established from these retrospective data, the main clinical message is that elderly patients receiving VDRAs, particularly those with CKD or relevant concomitant medications, require periodic calcium monitoring and prompt evaluation when nonspecific symptoms, AKI, or an elevated Na-Cl difference are observed.</p>","PeriodicalId":9697,"journal":{"name":"CEN Case Reports","volume":"15 6","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740417/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CEN Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13730-026-01207-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Vitamin D receptor activators (VDRAs) are widely prescribed for osteoporosis and CKD-mineral and bone disorder in Japan. Although hypercalcemia and acute kidney injury (AKI) are recognized adverse effects, metabolic alkalosis in these patients has received limited attention as a feature of calcium-alkali syndrome (CAS).We retrospectively reviewed patients with VDRA-associated hypercalcemia at our institution between April 2016 and June 2026, applying study-defined operational criteria for a CAS-like phenotype: hypercalcemia, elevated bicarbonate compatible with a metabolic alkalosis component (HCO₃⁻ ≥ 26 mmol/L), and AKI (KDIGO criteria). Seven elderly women fulfilled all criteria. Six received eldecalcitol (0.75 μg/day) and one received alfacalcidol (1.0 μg/day). Underlying CKD was present in six patients.Time from initiation to onset ranged from 1 to 120 months (median 18 months). Three cases had no identified exogenous alkali source. The serum Na-Cl difference was elevated in all patients (range 36-53 mEq/L). Renal outcomes were complete recovery in three patients, partial recovery in two, and non-recovery in one; one patient died of worsening heart failure.VDRA-associated hypercalcemia can present as a CAS-like phenotype even without calcium supplementation, and renal outcomes may be irreversible. Because the temporal relationship between hypercalcemia and metabolic alkalosis cannot be established from these retrospective data, the main clinical message is that elderly patients receiving VDRAs, particularly those with CKD or relevant concomitant medications, require periodic calcium monitoring and prompt evaluation when nonspecific symptoms, AKI, or an elevated Na-Cl difference are observed.

无补钙的维生素D受体激活剂相关钙碱综合征样表型:7例患者的病例系列
在日本,维生素D受体激活剂(VDRAs)被广泛用于骨质疏松症和ckd矿物质和骨骼疾病。虽然高钙血症和急性肾损伤(AKI)是公认的不良反应,但作为钙碱综合征(CAS)的一个特征,代谢性碱中毒在这些患者中得到的关注有限。我们回顾性地回顾了2016年4月至2026年6月期间在我们机构患有vdra相关高钙血症的患者,应用研究定义的cas样表型的操作标准:高钙血症,与代偿性碱中毒成分(HCO₃⁻≥26 mmol/L)相容的碳酸氢盐升高,和AKI (KDIGO标准)。7名老年妇女符合所有标准。6例给予依地骨化醇(0.75 μg/d), 1例给予阿法骨化醇(1.0 μg/d)。6例患者存在潜在的CKD。从开始到发病时间从1到120个月不等(中位18个月)。3例外源碱源不明。所有患者血清Na-Cl差异均升高(范围36-53 mEq/L)。肾脏预后为3例完全恢复,2例部分恢复,1例未恢复;一名患者死于恶化的心力衰竭。即使没有补钙,vdra相关的高钙血症也可以表现为cas样表型,肾脏结果可能是不可逆的。由于无法从这些回顾性数据中确定高钙血症和代谢性碱中毒之间的时间关系,因此主要的临床信息是,接受VDRAs的老年患者,特别是CKD或相关伴随药物的患者,需要定期进行钙监测,并在观察到非特异性症状、AKI或Na-Cl差异升高时及时评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CEN Case Reports
CEN Case Reports UROLOGY & NEPHROLOGY-
CiteScore
1.90
自引率
0.00%
发文量
80
期刊介绍: Clinical and Experimental Nephrology (CEN) Case Reports is a peer-reviewed online-only journal, officially published biannually by the Japanese Society of Nephrology (JSN).  The journal publishes original case reports in nephrology and related areas.  The purpose of CEN Case Reports is to provide clinicians and researchers with a forum in which to disseminate their personal experience to a wide readership and to review interesting cases encountered by colleagues all over the world, from whom contributions are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书